Catalent Reports Second Quarter Fiscal Year 2017 Results Post author:Sam Post published:February 6, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like FDA Grants Merck's Keytruda Priority Review for Cervical Cancer March 12, 2018 Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017 ProQR Therapeutics B.V. Announces Results For The Fourth Quarter And Full Year 2016 And Provides A Business Update February 27, 2017
Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017
ProQR Therapeutics B.V. Announces Results For The Fourth Quarter And Full Year 2016 And Provides A Business Update February 27, 2017